NASDAQ$IART

Integra LifeSciences Holdings Corporation · Q1 2025 earnings

Q1 2025 earnings · · Before market open · Investor relations

Briefing

Integra LifeSciences reported Q1 2025, revenue of $382.7M, a net loss of $25.3M.

For Q1 2025, Integra LifeSciences reported revenue of $382.7M, a net loss of $25.3M. The filing highlights segment performance, liquidity, and management commentary on the period.

  • Revenue $382.7M.
  • Net loss $25.3M.
  • Integra LifeSciences discusses capital allocation and near-term priorities in MD&A.

Headline financials

Total Revenue

$383M

Previous: $369M+3.7%
EPS (adj)

$0.41

Previous: -$0.04+1125.0%
Adjusted EBITDA

$63.6M

Previous: $71.8M-11.5%
Adjusted Gross Margin

62.2%

Previous: 64.4%-3.4%
Net Debt

$1.57B

No prior period
Total Leverage Ratio

4.3

No prior period
Total Liquidity

$1.16B

No prior period
Capital Expenditures

-$28.9M

Previous: -$15.5M-87.0%
Net Income

-$25.3M

Previous: -$3.28M-670.9%
Operating Income

-$15.5M

Previous: $3.96M-490.9%
Gross Profit

$194M

Previous: $207M-6.0%

Revenue & EPS history

Integra LifeSciences · Revenue · Quarterly

$383M

Q1 2025+3.7%vs Q1 2024
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Integra LifeSciences · $360M total across 4 segments · Q1 2021

  • Neurosurgery
    $189M+2.3%
  • Wound Reconstruction and Care
    $88.7M+22.7%
  • Instruments
    $52M+11.8%
  • Private Label
    $30.1M+3.4%

Forward guidance

Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.

Tailwinds

  • Headline results and segment trends anchor the quarter.
  • Liquidity and balance-sheet capacity support operations.
  • Strategic initiatives outlined in MD&A.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items affect year-over-year comparability.
  • Execution risk on growth or restructuring plans.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-0.2%

Avg return

Earnings day

-1.4%

Avg return

5 days after

-1.8%

Avg return

30 days after

51%

35 / 68 earnings

Positive

+29.2%

Q3 2024

Best reaction

-23.5%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+24.4%+31.0%+65.1%
Q4 2025-2.1%-8.9%-20.6%
Q3 2025-23.5%-26.8%-15.0%
Q1 2025-20.9%-27.3%-22.3%
Q4 2024+12.1%+5.3%-0.2%
Q3 2024+29.2%+28.5%+25.1%
Q2 2024-20.4%-23.5%-35.3%
Q1 2024-13.2%-10.0%+9.9%
Q4 2023-16.6%-18.8%-19.9%
Q3 2023-4.5%-5.8%+6.3%
Q2 2023-3.1%-1.1%-9.5%
Q1 2023-6.2%-5.5%-34.7%
Q4 2022+0.2%+0.8%-3.1%
Q3 2022+11.1%+12.7%+21.1%
Q2 2022-1.5%-0.5%-14.8%
Q1 2022+2.9%-0.2%+2.5%
Q4 2021+0.9%+2.6%-2.8%
Q3 2021+7.1%+7.5%-5.3%
Q2 2021-0.2%-0.3%+2.6%
Q1 2021-2.0%-3.4%-9.9%
Q4 2020-4.1%-2.8%-6.2%
Q3 2020-7.0%-4.5%+19.5%
Q2 2020+6.4%+6.6%-5.6%
Q1 2020+1.5%-2.8%+7.9%
Q4 2019+2.9%-0.3%-35.7%
Q3 2019-7.7%-5.1%-2.0%
Q2 2019+12.0%+14.5%+8.0%
Q1 2019-3.1%-2.3%-7.7%
Q4 2018+5.7%+6.1%+6.5%
Q3 2018-12.6%-13.5%-13.9%
Q2 2018-2.3%-2.3%-5.5%
Q1 2018+9.8%+12.7%+16.7%
Q4 2017-4.1%-4.1%+0.7%
Q3 2017-9.1%-8.2%-4.9%
Q2 2017-9.9%-10.7%-10.9%
Q1 2017+4.6%+5.1%+12.1%
Q4 2016-2.1%-1.2%-1.2%
Q3 2016+1.6%-3.4%+3.8%
Q2 2016+6.8%+6.4%+9.0%
Q1 2016+6.7%
Q4 2015+3.8%
Q3 2015+2.8%
Q2 2015-0.1%
Q1 2015+7.5%
Q4 2014+2.3%
Q3 2014-7.5%
Q2 2014+1.0%
Q1 2014-1.6%
Q4 2013-3.9%
Q3 2013+4.4%
Q2 2013-2.2%
Q1 2013+0.2%
Q4 2012-4.8%
Q3 2012-0.3%
Q2 2012+4.1%
Q1 2012+9.4%
Q4 2011+1.2%
Q3 2011-21.8%
Q2 2011-5.3%
Q1 2010+2.1%
Q1 2011+0.8%
Q4 2008-0.7%
Q4 2010-0.7%
Q3 2010+2.2%
Q3 2009+2.2%
Q2 2009+6.2%
Q2 2010+6.2%
Q4 2009+6.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro